Background and Purpose: Chronic obstructive pulmonary disease (COPD) is a common chronic inflammatory disease, which is associated with various comorbidities including osteoporosis. Interleukin(IL)-17 has been reported to play important roles in the pathogenesis of COPD and also associated with bone destruction in inflammatory diseases. However, the role of IL-17A in COPD-related osteoporosis is yet unknown. The purpose of our study was to investigate the potential contribution of IL-17A in COPD-related bone loss. Materials and Methods: We examined the bone mass and bone microarchitecture in wildtype and IL-17A -/-mice exposed to long-term cigarette smoke (CS). Osteoclast activities and the expression of receptor activator of nuclear factor-κB ligand (RANKL) in bone tissues were assessed, and the blood levels of inflammatory cytokines were measured. Results: Less bone loss as well as attenuated emphysema were shown in IL-17A -/-mice compared with wild-type mice. CS-exposed IL-17A -/-mice had decreased TRAP+ osteoclast numbers and lower RANKL expression compared with CS-exposed wild-type mice. Inflammatory cytokines including IL-6 and IL-1β in circulation were decreased in IL-17A -/-mice exposed to CS compared with wild-type mice.
Introduction
Chronic obstructive pulmonary disease (COPD) is a globally prevalent airway disease characterized by persistent inflammation and progressive airflow limitation caused by noxious particles or gases, particularly cigarette smoke (CS), 1 which is also commonly associated with extra-pulmonary comorbidities such as cardiovascular diseases, muscle wasting and osteoporosis. 2, 3 As one of the major systemic comorbidities of COPD, osteoporosis is associated with poor health status and prognosis of the disease. 4, 5 However, the underlying mechanistic links between COPD and osteoporosis remain elusive, although there is evidence suggesting that systemic inflammation, presumably resulting from "overspill" of inflammatory mediators from the lungs, may play key roles, among other factors, in the pathogenesis of COPD-related osteoporosis. 6, 7 Studies have shown that bone and immune cells, particularly activated T cells including Th17 cells, are functionally connected. 8, 9 For example, CD4+ T cells produce both proinflammatory cytokines such as IL-17, and the osteoclastogenic cytokine RANKL, which was found to be dysregulated in COPD in our previous study. 10 IL-17, mainly produced by Th17 cells, has been found to play important roles in the pathogenesis of COPD. 11, 12 Expression of IL-17A was increased in airways of COPD patients and correlated with lung function decline. 13, 14 Besides, data from animal models have suggested a critical role for IL-17A in CS-induced lung inflammation and emphysema. 15, 16 Interestingly, IL-17 is also a key molecule in osteoimmunology. As a potent osteoclastogenic cytokine, IL-17A was found to increase RANKL expression in osteoblasts and synovial fibroblasts, enhancing the formation and activation of osteoclasts and bone destruction in rheumatoid arthritis. 17, 18 While the involvement of IL-17 in bone metabolism has been demonstrated in inflammatory diseases, 19 and longterm CS exposure is associated with bone loss, 20,21 the role of IL-17 in COPD-related osteoporosis is yet unknown. Therefore, in this study, we employed a long-term CS exposure mouse model to investigate the potential role of IL-17A in COPD-related osteoporosis. The results revealed that long-term CS exposure induced emphysema as well as bone loss in mice, and IL-17A deficiency was associated with attenuated emphysema and less bone loss in this model, suggesting that IL-17A may be a common mechanistic link between CS-induced COPD and osteoporosis.
Materials and Methods Animals
Female wild-type (WT) C57BL/6 mice (6-8 weeks of age, 20-25g body weight) were purchased from Beijing Vital River Experimental Animal Company (Beijing, China). IL-17A -/-mice on the C57BL/6 background (generated by Dr. Yoichiro Iwakura, and provided by Dr. Huanzhong Shi, Capital Medical University) were bred in house. All mice were housed in sterilized cages under a 12-h light-dark cycle, with free access to sterilized food and water. All experimental protocols and procedures complied with the guidelines of the Committee of Peking University on the care and use of laboratory animals, and were approved by the Ethical Committee for Animal Research of Peking University Third Hospital.
Cigarette Smoke Exposure
Wild-type mice and IL-17A -/-mice were, respectively, divided randomly into two groups: control groups and CSexposed groups. Mice were exposed to active smoke generated by commercially available cigarettes (Baisha cigarettes with filter purchased from Hunan, China) using a nose-only smoke exposure system (SG-300; SIBATA, Tokyo, Japan), as described previously in our study. 22 Briefly, each mouse was restrained in an individual exposure chamber and exposed nose-only to diluted cigarette smoke. A computercontrolled suction was generated, with 20mL CS per 8 seconds into the inhalation tower. The optimal smoke: air ratio of 1:9 was obtained. Animals were exposed twice a day for 50 mins, 5 days per week for 24 weeks. The control animals were exposed only to filtered air in the same duration.
Lung Function Measurements
At the end of the 24 weeks CS exposure, each mouse was deeply anesthetized with intraperitoneally administered pentobarbital sodium. Tracheostomy was performed, and the trachea cannulated. After intubation, the tracheal cannula was attached to a Flexivent ventilator (Scireq, Montreal, QC, Canada), and lung mechanics were measured following the protocol described previously. 22 The ventilation rate was set at 150 breaths per min with a tidal volume of 10 mL/kg and a positive end-expiratory pressure of 2cm H 2 O. Total lung capacity (TLC), airway resistance (R) and lung dynamic compliance were measured and recorded.
Lung Histology and Measurement of Emphysema
Mouse lung tissues were obtained and fixed with 4% paraformaldehyde for 24 hrs, and then embedded in paraffin, cut into sections of 4 μm thickness, followed by H&E staining. Airspace enlargement was measured by the mean linear intercept (Lm) and destruction of alveolar walls was quantified by the destructive index (DI) according to described protocols. 23 
Microcomputed Tomography of Bones
Mouse femurs were dissected and fixed in 4% paraformaldehyde. Distal femurs were scanned using microcomputed tomography (SkyScan 1172; Kontich, Belgium) with a 5µm voxel size. X-ray source was set at a voltage of 45 kV with a 0.5 mm aluminium filter. Scanning angular rotation was 180°and images were captured every 0.4°. Three-dimensional (3D) reconstruction was carried out using SkyScan NRecon software and data were analyzed using CT-Analyzer software. For trabecular measurement, region of interest (ROI) was drawn starting from 0.5mm proximally to the growth plate over 2 mm in the proximal direction, and the cortical ROI was drawn from 3.25 mm proximally to the growth plate with 0.5 mm of thickness as described previously. 24 Bone morphometric parameters were measured by CTAnalyzer software, including trabecular bone volume (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), structure model index (SMI). BMD values were calculated from calcium hydroxyapatite micro-CT phantoms and were averaged for the volumes of interest.
Histochemistry and Immunohistochemistry of Bone Tissues
At the time of sacrifice, mouse femurs were fixed in 4% paraformaldehyde for 24 hrs, decalcified in 10% EDTA for 21 days and embedded in paraffin. The osteoclast marker tartrate-resistant acidic phosphatase (TRAP) was detected using TRAP staining kit (Servicebio, Wuhan, China). Briefly, paraffin sections were routinely dewaxed in water and incubated with the TRAP activity mix for 1 h at 37°C. For immunohistochemistry of RANKL, bone tissue on slides was treated with 0.3% H 2 O 2 for 10 min to block endogenous peroxidase. Antibodies against RANKL (1:150, Santa Cruz Biotechnology, CA) were added and incubated at 4°C overnight. After incubation with peroxidase-conjugated secondary antibody, signals were visualized with a DAB peroxidase substrate kit. Cancellous bone was assessed starting from the lower edge of the growth plate and extending proximally by 4 mm. Images were captured using Olympus BX51 microscope, and cells per bone perimeter (B.Pm) or per bone marrow area was measured to evaluate the number of positive cells with Image Pro Plus 6.0 software (Media Cybernetics, MD, USA) as previously described. 25 
Cytokine Measurements
Serum levels of IL-6 (BMS603/2 eBioscience, USA) were determined using commercial ELISA kits. Serum levels of IL-1β, TNF-α and IL-17A were measured by Procarta cytokine assay kit (Affymetrix eBioscience, San Diego, CA, USA) according to the manufacturer's protocol.
Statistical Analysis
All statistical analyses were performed using the SPSS20.0 software (IBM Corporation, Armonk, USA). Data are presented as mean ± SD. Statistical analysis was performed by one-way ANOVA test (equal variances assumed) or Tamhane's T2 signed-rank (equal variances not assumed). Differences were considered significant at p-value <0.05.
Results

IL-17A Contributed to CS-Induced Airspace Enlargement and Lung Inflammatory Response
Following 24 weeks CS exposure, mouse lung function and morphometric assessment of lung sections were performed. Wild-type mice receiving chronic CS exposure exhibited impaired pulmonary function, a significant increase in total lung capacity and airway resistance ( Figure 1A-B) , as compared to those exposed to air only. Histological analysis of lung sections showed alveolar enlargement as well as increased inflammatory cell infiltration in the lung parenchyma and interstitial spaces ( Figure 1C -F), indicating that COPD-like responses were successfully induced in CS-exposed mice.
In contrast, in IL-17A-deficient (IL-17A -/-) mice exposed to CS, the changes in total lung capacity ( Figure 1A ) and emphysema were partially ameliorated, as demonstrated by a statistically decreased DI and Lm ( Figure 1E-F) , as well as decreased inflammatory cell infiltration in lung tissues ( Figure 1C ). These results indicated that IL-17A contributed to COPD-like changes in our murine model.
Deletion of IL-17A Was Associated with Attenuated Bone Loss in Mice with Chronic CS Exposure
To explore the potential role of IL-17A in bone loss in mice exposed to CS, bone microarchitecture of the femur was assessed using high-resolution micro-computed tomography (microCT). Three-dimensional reconstruction images of trabecular bones and cortical bones showed that the bone microarchitecture was significantly altered in CS-exposed wild-type mice, with thinner and less dense trabeculae, as well as reduced connectivity, which were ameliorated in IL-17A -/-mice with CS exposure (Figure 2A) . Moreover, quantitative analyses showed that in wild-type mice exposed to CS, as compared to those exposed to air, a significant decrease in trabecular thickness (Tb.Th) as well as bone mineral density (BMD) of the trabeculae and cortical bone were observed, whereas in IL-17A -/-mice with CS exposure, these changes were significantly attenuated ( Figure 2B-D) . Bone volume (BV/TV) was also significantly decreased in wild-type mice exposed to CS (P<0.05), but showed a trend toward increase in IL-17A -/-mice with CS exposure (P=0.081) ( Figure 2E ). However, structural model index (SMI) and trabecular spacing (Tb.sp) showed no significant change ( Figure 2F-G) . Taken together, these results indicated that IL-17A was also involved in bone loss in CSexposed mice.
Osteoclastogenesis and RANKL Expression Were Downregulated in Bone Tissues of CS-Exposed Mice with IL-17A Deletion
As osteoclasts were the only cells definitively shown to degrade bone, 26 we therefore performed TRAP staining on paraffin-embedded femur sections to examine osteoclastic activity in bone of CS-exposed mice. Marked TRAP+ osteoclast cells on the surface of bone were seen in wildtype mice with CS exposure, whereas a significantly decreased number of TRAP+ osteoclast cells were found in IL-17A -/-mice with CS exposure (Figure 3A-B) .
As RANKL was a canonical mediator in osteoclast differentiation and bone destruction, 27 and in our earlier study circulating RANKL was found increased in COPD patients with lower BMD, 28 we, therefore, performed immunohistochemistry for RANKL in bone tissues. We found marked RANKL staining in wild-type mice exposed to CS as compared to those exposed to air, but its expression was decreased in IL-17A
-/-mice with CS exposure ( Figure 3A and C). These data suggest that IL-17A may be involved in osteoclastogenesis via enhancing local expression of RANKL in bone tissues in this model. 
IL-17A Deficiency Was Associated with Downregulation of Pro-Osteoclastic Inflammatory Cytokines in Circulation
Several proinflammatory cytokines have been reported to be responsible for bone destruction. 29 Therefore, we examined the serum levels of cytokines IL-1β, IL-6, and TNF-α, which were potentially associated with both COPD and bone loss. Our results showed that chronic CS exposure was associated with upregulation of IL-1β, IL-6, and TNF-α, as well as IL-17A ( Figure 4A-D) . By contrast, the levels of IL-6 and IL-1β were decreased in CS-exposed IL-17A -/-mice as compared with wild-type mice exposed to CS ( Figure 4B-C) , whereas the levels of TNF-α remained unaffected ( Figure 4D ), suggesting that IL-17A may also promote bone loss indirectly by modulating some of the pro-osteoclastic cytokines.
Discussion
While accumulating evidence has implicated IL-17 in the pathogenesis of both COPD 30, 31 and osteoclastogenesis associated with inflammatory diseases, 19 its role in osteoporosis of COPD has not been established. In this study, for the first time to our knowledge, we demonstrated that IL-17A contributed to bone loss induced by long-term CS exposure in a well-established mouse model of COPD, probably through its proinflammatory effects and upregulation of RANKL expression in bone tissues. Osteoporosis is a major comorbidity of COPD. In a systemic review by Graat-Verboom et al, the overall mean prevalence of osteoporosis in COPD was 35.1% (272 of 775 patients), although a large variation was observed because of differences in patients enrolled, methods and definitions used for osteoporosis. 32 Osteoporosis may cause fractures, impair mobility, increase morbidity and mortality, and therefore carries a poorer outcome of COPD. 5 Understanding of the pathogenesis of osteoporosis associated with COPD is imperative for prevention and targeted interventions. However, the mechanisms underlying exaggerated bone loss in COPD remain speculative. 33 For example, it has been hypothesized that inflammation in the lung results in "overspill" into the circulation causing systemic inflammation which triggers osteoporosis. 6 It is also interesting to note that in smokers, radiographic emphysema was a strong, independent predictor of low BMD, and this relationship suggested that there may be common mechanistic links between emphysema and osteoporosis. 34 In a most recent study, Tsukamoto et al observed systemic bone loss in a mouse model of elastase-induced pulmonary emphysema, strongly suggesting a potential link between emphysema and osteoporosis. 35 However, in CS-exposed mouse models, the effect of CS on bone was inconsistent, depending on the routes and duration of CS exposure. In a recent study, Sasaki et al found, in a nose-only CS exposure mouse model, that only prolonged (20-40weeks) exposure led to bone resorption. 20 In the current study, we used a same exposure system, and found that 24 weeks CS exposure caused bone loss, as well as emphysema consistent with COPD. In agreement with previous studies, 15 we confirmed the critical role of IL-17A in development of lung inflammation and alveolar destruction in this model, and more importantly, we made the novel finding that deficiency of IL-17A attenuated bone loss together with attenuated emphysema. These results indicated that IL-17A might be one of the common links between emphysema and osteoporosis associated with chronic cigarette smoking.
Bone is a dynamic organ undergoing continuous remodeling via bone resorption and formation. At the cellular level, the occurrence of osteoporosis mainly results from excessive bone resorption by osteoclasts. 36 Although the activities of osteoclasts are reported to be regulated by several factors, including the RANKL-RANK-OPG pathway, estradiol and various cytokines, only RANKL is indispensable for osteoclast differentiation and activation. [37] [38] [39] In our previous studies, we found increased RANKL levels in peripheral blood of COPD patients with osteoporosis. 10, 28 Thus, in this animal study, we further investigated osteoclast activities and RANKL expression in bone tissues, and as expected, our data demonstrated that long-term CS exposure was associated with significantly higher numbers of TRAP+ osteoclasts, and local upregulation of RANKL expression. Interestingly, we also observed that IL-17A deficiency reduced the numbers of osteoclasts as well as RANKL expression in bone tissues of CS-exposed mice, suggesting involvement of IL-17A/RANKL axis in regulating bone resorption in this CS-exposed model. Although the direct effects of IL-17A on differentiation of osteoclast precursors into osteoclasts remain controversial, 40, 41 there is evidence suggesting that IL-17A induces osteoclast formation via RANKL expression from other cells. For example, one in vitro study revealed that IL-17 induced differentiation of osteoclast progenitors into mature osteoclasts by stimulating RANKL expression in osteoblasts. 17 In collagen-induced arthritis mice, overexpression of IL-17 in the knee joint promoted osteoclastic bone destruction by enhancing RANKL expression in the synovium. 42 Taken together, in our animal model, long-term CS-induced boss loss was dependent, at least partially, on the IL-17A/ RANKL pathway. As our previous study in COPD patients revealed an association of lower BMD with higher serum levels of inflammatory cytokines including TNF-α, IL-1β, and IL-6, 28 which are well-known inducers of osteoclasts leading to increased bone resorption, 43 we further explored whether these systemic inflammatory mediators were dysregulated and associated with IL-17A in this model. The results showed that CS-exposed mice exhibited elevated proinflammatory cytokines, including IL-17A, TNF-α, IL-1β, and IL-6, in circulation. It is worth noting that mice deficient of IL-17A had lower IL-1β and IL-6 expression. Consistently, experimental studies by others had shown that IL-17A was able to promote the production of IL-1β, IL-6, TNF-α by macrophages, 44 and in collagen-induced arthritis mice, IL-17A increased the synovial expression of IL-1β and IL-6. 45 Our findings here suggest a regulatory role of IL-17A in production of proinflammatory cytokines, which are probably involved in CS-induced osteoclastogenesis in this model. One limitation of our study is the lack of evidence to demonstrate whether bone loss is consequent on lung disease, as cigarette smoking was associated with lower BMD independently of COPD, 34 and certain components in cigarettes could directly induce osteoclastic bone resorption. 46 Although the critical role of IL-17 in CSinduced emphysema is clear in our mouse model, its independent role in bone loss cannot be established. Considering the complexity of pathogenesis of COPD and its comorbid conditions, a causal relationship is technically difficult to demonstrate. Deleting IL-17 in specific organ systems may be useful to reveal its role in certain comorbidities of COPD in future studies.
Conclusion
Taken together, our study revealed the critical role of IL-17A in long-term CS exposure-induced emphysema and bone loss in mice, supporting IL-17A as a common mechanistic link between CS-induced COPD and osteoporosis. These results provide novel insights into the mechanisms underlying COPD and its major comorbidities.
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